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ESTThe human liver plays a vital role in meeting the body's metabolic needs and maintaining homeostasis. To
address the molecular mechanisms of liver function, we integrated multiple gene expression datasets from
microarray, MPSS, SAGE and EST platforms to generate a transcriptome atlas of the normal human liver. Our
results show that 17396 genes are expressed in the human liver. 238 geneswere identiﬁed as liver enrichment
genes, involved in the functions of immune response andmetabolic processes, from theMPSS and EST datasets.
A comparative analysis of liver transcriptomes was performed in humans, mice and rats with microarray
datasets shows that the expression proﬁle of homologous genes remains signiﬁcantly different between
mouse/rat and human, suggesting a functional variance and regulation bias of genes expressed in the livers.
The integrated liver transcriptome data should provide a valuable resource for the in-depth understanding of
human liver biology and liver disease.nome Center at Shanghai, 351
21 50800402.
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The liver is the largest organ in the human body and is likely
second only to the brain in complexity. It is also a vital multifunctional
organ present in vertebrates, playing a key role in digestive function
andmetabolism. In addition, the liver has a number of other functions,
including generation of red blood cells during embryonic develop-
ment, production of various plasma proteins, detoxiﬁcation of
xenobiotics, and phagocytosis of solid material. It also forms a
protective barrier between the digestive tract and the rest of the
body. The liver plays a vital role in the activation, catabolism and
excretion of retinols, which are essential to vision, growth, reproduc-
tion, immunity, and cell proliferation and differentiation. Additionally,
the liver is involved in many important diseases [1], which cause a
variety of symptoms related to digestive problems, blood sugar
abnormalities, immune disorders, abnormal absorption of fats, and
metabolic problems. Furthermore, as the liver is a major organ of drug
elimination, it has a signiﬁcant effect on drug metabolism. However,the molecular mechanisms of liver function have not been completely
characterized to date.
High-quality transcriptome data are helpful for proteomic analyses
of tissue. Human liver transcriptome data allow the (data-based)
integration of transcriptome data with corresponding proteome data,
as well as scaling protein identiﬁcation (data-based) and protein
linkage map (cDNA-based) data during liver proteome analysis. The
establishment of an accurate transcriptome atlas of human liver tissue
is also critical for elucidating the pathogenesis and treatment of liver
diseases [2]. Toward this end, prior studies have investigated the
transcriptomes of several human liver samples, including fetal liver
[3], adult liver [4], and liver cancer [5]. Some liver enrichment genes
have been reported to play key roles in biological process and disease
development [6,7]. However, the precise transcriptome atlas of
healthy human liver tissue is still unavailable.
To provide a valuable resource for the in-depth understanding of
human liver biology and liver disease, as well as a reference dataset
for the Human Liver Proteome Project, we integrated multiple gene
expression datasets from different platforms to generate a transcrip-
tome atlas of the normal human liver. Meta-data from gene
expression experiments were used to identify liver enrichment
genes and their biological functions. We also identiﬁed groups of
genes that are differentially expressed in human liver by comparing
homologous gene pairs in mice and rats. Gene ontology and pathwayeserved.
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gene groups. Transcription factor usage biases in different groups
further revealed differences in the regulation of genes with different
expression levels. This study was designed to contribute to our
understanding of gene expression patterns and diverse biological liver
processes of different species. The liver transcriptome map con-
structed in this work may serve as a resource for human hepatic
proteomics studies and disease treatment research.Fig. 1. Expressed genes in normal human liver. This ﬁgure illustrates the number of
expressed genes in normal human liver identiﬁed according to four types of
transcriptase expression detecting methods. The numbers in parenthesis represent
the genes proved by two datasets along the cater-corner. (e.g., the number of expressed
liver genes detected in Microarray and EST experiments is 2643.).2. Results
2.1. Overview of the transcriptome of the adult human liver
In order to further understand liver biology, we have integrated
multiple transcriptomic datasets from different platforms: micro-
array, MPSS, SAGE and EST (see in Materials and methods). The
dataset of MPSS and partial microarray datasets were obtained from
the gene expression proﬁling of 10 adult human liver tissues from the
resource of Chinese Human Liver Proteome Project (CNHLPP), while
the rest data were using as supporting data derived from public
databases. 11435 genes were detected to be expressed using the
CNHLPP samples with microarray and MPSS dataset, most of which
were also proved by the other public datasets (Table 1). Using all four
kinds of datasets, any gene that appears in one or more of these
datasets will be considered as a candidate for further study of genes
expressed in human liver. The gene should contain at least one
scanned sequence in theMPSS, SAGE or EST dataset or contain Present
probes in the microarray dataset (see Materials and methods). We
found that a total of 17396 genes were expressed in human liver
(Table S1). Of the 17396 candidate genes, 13456 genes were derived
from microarray data, 6720 genes from the MPSS dataset, 7770 genes
from SAGE data, and 13615 genes from the EST data. A total of 3588
genes were found in all four of the datasets (Fig. 1 and Table 1).
Interestingly, the correlation coefﬁcient between the MPSS dataset
and the EST dataset was 0.88, while the correlation coefﬁcients
between the other dataset pair, namely MPSS and SAGE, SAGE and
EST, and SAGE and microarray, were 0.47, 0.40, and 0.43, respectively.
The data suggest that MPSS and EST data are, in general, highly
correlated to one another, while the correlation between the other
datasets is weak (Fig. S1 in the supplementary ﬁles). This ﬁnding
indicates that different platforms have biases toward distinct
transcripts. Given these biases, using multiple techniques for gene
expression proﬁling is advised.Table 1
Cross dataset overlap in human liver transcriptome (unigene based).
Summary Data resource comparison
CNHLPP resource Public resources
MPSS microarray microarray SAGE EST
Identiﬁed gene 6720 9862 13316 7770 13615
Unique gene 179 88 2169 501 1986
Overlap between CNHLPP
and public datasets
Totally 11435 genes
from CNHLPP
10680 5791 9414
Overlap between each pair
of datasets
microarray (13456) SAGE EST
MPSS 6194 3892 5989
microarray 6181 10384
SAGE 5989
Total gene from all
resources
17396
This table illustrated the summary of gene expressed in liver from different platforms.
The “Unique gene” represented those genes identiﬁed in the dataset from only one
platform. The “Overlap between CNHLPP and public datastes” represented the number
of genes proved to be expressed in liver according to CNHLPP and one of the public
datasets. The “Overlap between each pair of datasets” represented the number of genes
proved to be expressed in liver according to each two of the public datasets.In addition, we wished to evaluate whether low abundance genes
(genes containing only one copy in any of SAGE, MPSS, or EST data or
associated with a low expression intensity in the microarray
database) in our integrated dataset were reliably expressed in the
human liver. To answer this question, we used reverse transcription
polymerase chain reaction (RT-PCR) to detect their transcripts in a
pooled sample from 10 adult liver tissues. Twenty genes were
randomly selected from each platform for the analysis (Table S2).
The results showed that the transcripts of the 19 genes examined
were indeed detected in the human liver sample at different levels
(Fig. 2). This suggests that the transcripts detected at low levels by the
various assays were, in fact, expressed in the liver andwere detectable
using RT-PCR. These low expressed genes in human liver are mainly
enriched in such Gene Ontology [8] modules as multicellular
organismal development (GO:0007275), neurological system process
(GO:0050877) and so on (Table S18).
To characterize the molecular features of human liver, those genes
considered to be expressed in the liver were then assigned to different
functional categories based on Gene Ontology. Out of 17396 candidate
genes 13266 genes have functional information in Gene Ontology, in
which 10985 were predicted to be localized on cellular components,
including cell (58.7%), extracellular (4.9%), envelope (2.1%) and
organelle (34.9%) (Table S3). Moreover, 11891 of the analyzed
genes were assigned to categories based on molecular function. The
largest category, which included 25.3% of the genes, was predicted to
exhibit catalytic activity. In addition, 10962 genes were predicted to
play important roles in biological processes, such as cell communi-
cation (15.7%), regulation of cellular signaling (18.8%), cell death
(3.7%) and cell growth (0.9%). Of the 6782 genes categorized under
metabolic processes, the majority were involved in protein metabo-
lism (16.0%), nucleic acid metabolism (17.1%), lipid metabolismFig. 2. RP-PCR evidence for liver expressed gene with low signals. 20 genes with low
signals were randomly selected for the evaluation of those signatures via RT-PCR,
where H2O were employed as negative controls and Beta-actin as a positive control.
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liver is a major organ for nutrient metabolism. As expected, a few
genes were also classiﬁed as being involved in the metabolism of
other substances, such as drugs (39 genes), aldehydes (15 genes), and
alcohol (259 genes), suggesting that these basic metabolic processes
are necessary for adult liver function.
To further explain the bias in the context of the detected transcripts,
we identiﬁed about 4000 genes using either the microarray or EST
dataset. According to our Gene Ontology enrichment analysis, the
microarray platform detected more membrane-protein-related liver
genes, while more intermediate ﬁlament cytoskeleton genes were
found using the EST platform. Moreover, those genes found only
through microarray analysis were strongly involved in certain path-
ways, such as cell communication and the smoothened signaling
pathway, while the EST-speciﬁc genes were found to be linked with
leukotriene metabolism and detection of light and/or abiotic stimuli
(Table S4). Together, these ﬁndings suggest that the method-speciﬁc
bias in transcript detection is also reﬂected in gene function.
To explore the relationship between the transcriptome and the
proteome, we investigated the correlation between the genes
expressed in liver at protein level and those expressed at mRNA
level. We compared the Human Protein Atlas dataset [9] derived from
48 human tissues including a total of 3168 proteins screened by
antibodies with our integrated liver dataset, of which 2340 proteins
are proved to be expressed in human liver tissue. All genes with
strong or moderate intensity in the Human Protein Atlas dataset were
grouped into the “protein expressed” category, while those with
negative intensity were grouped into the “protein unexpressed”
category. Wilcoxon signed-rank tests were performed between the
two groups in each dataset to prove the statistical signiﬁcance of the
results. The p-values for the microarray, MPSS, SAGE and EST datasets
were 1.106E-06, 2.145E-4, 5.686E-06 and 1.166E-07, respectively. Our
results show that those in 'protein expressed' group exhibit higher
intensity/signal at the gene expression level than those in the
“protein unexpressed” group (Fig. 3). According to GO enrichment
analysis, such GOmodules as signal transducer activity (GO:0004871)
and molecular transducer activity (GO:0060089) might be enriched
with protein unexpressed genes (Table S19).Fig. 3. Expression data for liver expressed protein. This ﬁgure illustrates four types of transcri
unexpressed genes. The protein expressed and unexpressed groups were deﬁned according
expression intensity.2.2. Identiﬁcation of liver enrichment genes
To identify the genes expressed speciﬁcally in human liver, we
downloaded MPSS data of 32 human normal tissues [10] deposited in
GEO (NCBI), as well as EST data from the dbEST of 45 normal human
tissues (http://www.ncbi.nlm.nih.gov/dbEST/). In total, 1574 genes
with adjusted p-values of less than 0.05 were considered potential
liver enrichment genes from the MPSS dataset. Similarly, we
identiﬁed 2808 candidate liver enrichment genes from the EST
dataset. To remove the biases from different technology platforms,
we selected 238 genes (gene ID) overlapped in both datasets and
considered them as the liver enrichment genes (Table S5). Many
genes among these, such as ALB (the gene with the highest frequency
across all four datasets) and apolipoproteins (APOA, APOB, and APOC),
are known to be associated with liver function. For example, ALB,
which is secreted by hepatocytes, functions primarily as a carrier
protein for steroids, fatty acids, and thyroid hormones and plays a role
in stabilizing extracellular ﬂuid volume. Apolipoproteins are known to
play important roles in lipid metabolism and in maintaining the
balance of lipoproteins in plasma. Interestingly, many genes with
unknown functions, such as LOC145663, C10orf54 and SLC25A47,
were also found to be expressed speciﬁcally in the liver. Whether
these genes are involved in liver function should be a focus of future
investigations. Compared with 238 liver-enriched genes, only 84
liver-enriched proteins were found in Human Protein Atlas database
(Table S13). The inconsistency between transcription and translation
levels maybe due to currently fewer proteins deposited in the Human
Protein Atlas database that have been screened against antibodies in
liver tissue than the genes in our integrated transcriptional database.
To investigate the biological function of liver enrichment genes,
gene ontology enrichment analysis was performed. This analysis was
conducted on those Gene Ontology (GO) models (including biological
process, cellular component, and molecular function) containing over
10 genes considered in our study. The details of the enriched GO
classes and their adjusted p-values can be found in the supplementary
ﬁles (Fig. 4 and Table S6). Such models as regulation of immune
system processes (GO: 0002682) and response to inﬂammation (GO:
0002526), wounding (GO: 0009611), stimulus (GO: 0009605), andptional expression data (Microarray, MPSS, SAGE and EST) for liver protein expressed or
to signals from Human Protein Atlas dataset. The Y-axis represents the LOG transferred
Fig. 4.Human liver speciﬁc GOmodels. Enriched GOmodels for liver speciﬁc genes were displayed in a network illustration. Red nodes represent enrichedmodels for biology process
class, blue nodes for molecular function and green nodes for cellular component.
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with this group of genes. Also, the liver enrichment genes were
enriched for metabolic-related processes such as carboxylic acid
metabolism (GO: 0019752), organic acid metabolism (GO: 0006082),
lipid metabolism (GO: 0006629), and steroid metabolic processes
(GO: 0008202).
Moreover, these 238 potential liver enrichment genes were
mapped onto human chromosomes based on genomic information
(GeneMap'99) [11]. Some liver enriched genes, such as 3p21, 6p21,
14q32 and 19p13, were clustered onto certain chromosomes or
regions of chromosomes (Fig. S2: the locations of liver-expressed
genes and liver enrichment genes).
To further understand the functions of liver enrichment genes, a
text mining strategy was employed to discover the relationship
between these genes and certain types of cancer and other diseases.
Our results showed that some liver enrichment genes have association
with multiple diseases, including cancers or other non-tumor-related
diseases (Tables S7 and S8). For instance, the members of cytochrome
P450 family (CYP family), involved in a myriad of biological processes,
were found to be frequently dysregulated in many diseases including
liver cancer and other cancers (prostate cancer, breast cancer,
Leukemia and so on). While dysregulation of GNMT (glycine N-
methyltransferase), APOA (apolipoprotein), and ADH (alcohol dehy-
drogenase) inclined to contribute to heptocarcinomagenesis. Further-more, some other digestive system disorders also showed a close
relationship to liver enrichment genes (Tables S7 and S8). Our ﬁnding
suggested that the liver enrichment genes have multiple biological
functions and might play critical roles in the development of multiple
diseases including liver cancer as well as other neoplasms.
We downloadedMPSS data (GSE1581) of 44mouse normal tissues
[10] deposited in GEO (NCBI). Using a similar computational strategy
of identiﬁcation of human liver-enriched genes to candidate mouse
liver enrichment genes, a total of 219 genes (Gene ID) were found to
be enriched in mouse liver (pb0.05). Out of 219 mouse liver
enrichment genes, 65% (142/219) genes have homology with
human. Of 142 genes 60% (85/142) ones which were also enriched
in human liver (Table S14) were mainly involved in the functions,
such as response to stimulus(Table S15), suggesting that human liver
and mouse liver have certain similar function at response to stimulus.
While the remaining 40% (57/142) which were not found to have a
similar pattern in human liver were often involved in the metabolic
processes of lipid, carboxylic acid and organic acid (Table S16).
2.3. Comparative analysis of liver transcriptomes in human, mouse and rat
Weusedmicroarraydatasets to performa cross-species comparative
analysis of liver transcriptomes in human, mouse and rat. A total of
62.54% of the probes identiﬁed were expressed (P) in human (GPL570)
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methods). Thedetection rates inmouse and ratwere60.08%and62.22%,
respectively. These probeswerematched to 13456 human genes, 14326
mouse genes, and 10525 rat genes, all of which were considered in our
analysis.
All homologous pairs in human and mouse (in human and rat, in
mouse and rat) were assigned to six groups, according to their
expression proﬁling in liver, after ﬁltering out those genes not
included in our study's microarray platform (Tables 2, S10, S11 and
S20). Less than half of the homologous pairs in human and mouse
showed similar expression states in our study (non-speciﬁc liver
genes, inter-species), and others shown either to have nearly equal
levels of expression or to be silenced in the liver (Type III and Type VI).
Around one fourth of the human genes are more active than their
homologous genes in mouse (Type I and Type II): 10.9% of the
homologous genes were found to be unexpressed, and 19.2% showed
relatively lower expression rates in mouse. The rest of the human
genes consideredwere found to be expressed at a lower level in human
liver than their homologous genes in mouse (Type IV and Type V,
mouse/rat speciﬁc liver genes). The homologous gene pairs in humans
and rats show trends similar to those in humans andmice. Almost half
of the homologous gene expression patterns identiﬁed from the
human/rat analysis were identical to those in the human/mouse
analysis. The gene expression similarity in mouse and rat homologous
genes is more signiﬁcant than that in human and mouse (or human
and rat) homologous genes. Two homologous gene families in each
gene expression type (Type I to Type VI) and total 12 gene families (G1
to G12) were randomly picked to be validated in human, mouse and
rat liver tissues by Quantitative real time PCR (see in Materials and
methods). The results have shown that the identiﬁcation of gene
expression type in our study was reliable (Fig. S3).
According to the GO model enrichment analysis in the context of
differently expressed homologous pairs, those genes that are more
strongly expressed in humans mainly include metabolism-related
classes. Classes such as monosaccharide metabolic processes (GO:
0005996) and lipidmetabolic processes (GO: 0006629) are signiﬁcantly
enriched for the Type II group. Those genes that are not expressed in
human liver were enriched with respect to neurological processes and
cell signaling-related GO classes, such as nervous system development
(GO: 0007399), G-protein-coupled receptor protein signaling pathway
(GO: 0007186), and cAMP-mediated signaling (GO: 0019933). Most of
the ﬁndings regarding human liver gene function enrichment were
conﬁrmed in the comparisons betweenmouse and rat. Pathwayanalysis
is a particularly effectiveway to examine the reliability of theﬁndings in
the GO enrichment analysis. For human liver homologous genes in the
human/mouse comparison, 14 pathwayswere found to be signiﬁcantly
altered in our enrichment analysis (Table 3). Five pathways (oxidative
phosphorylation, carbon ﬁxation, proteasome, citrate cycle and ubiqui-
none biosynthesis) sharedmore highly expressed genes in human liver.
Non-speciﬁcally expressed genes focused on regulatory housekeeping
pathways like DNA polymerase and the cell cycle. Those genes found to
be unexpressed in human liver from the Type V and VI groups are
involved in pathways such as neuroactive ligand–receptor interaction,Table 2
Expression based types of homology pairs in human, mouse and rat.
Type Homology pair
Human–mouse % Human–rat % Mouse–rat
I 2150 10.9% 1,662 13.2% 1,445
II 3290 16.7% 1,825 14.5% 1,492
III 6973 35.3% 3,468 27.6% 11,641
IV 3786 19.2% 3,738 29.7% 3,731
V 1468 7.4% 749 6.0% 916
VI 2088 10.6% 1,142 9.1% 1,437
summary 19,755 12,584 20,662cell communication, and the calcium signaling pathway. Transcription
factor enrichment analysis showed that target genes of a few
transcription factors were concentrated in certain types of homologous
genes (Table 4). For example, most of the target genes of JUN were
expressed in human liver, while their homologous genes inmousewere
unexpressed. A total of 15 transcription factors in human liver contain
target genes signiﬁcantly enriched in one or two expression types of
homologous genes.
3. Discussion
In this study we proposed a strategy to construct the transcrip-
tome atlas of human liver using multiple types of gene expression
data. The identiﬁcation of liver-transcribed genes using a single
expression proﬁling technique faces numerous problems, such as
limited sequence libraries, a lack of detection sensitivity, and
unavoidable technique error. Genes with very weak signals from
each dataset were shown to be expressed in liver using an RT-PCR
experiment. CDH18, which is expressed speciﬁcally in the central
nervous system and is putatively involved in synaptic adhesion, axon
outgrowth and guidance, may be a false-positive candidate liver-
expressed gene according to our RT-PCR results. Our study suggests
that this approach is useful for integrating large-scale gene transcrip-
tion proﬁling data to construct a transcriptome atlas of human liver.
The difference between transcriptome and proteome was largely
expected and likely caused by many factors, including the variance in
the process of translation of mRNA to protein. The correlation
between protein signal and expression status detected in our work
validates our meta-analysis in the context of integrated transcriptome
and proteome data.
A functional assessment was provided by the Gene Ontology (GO)
and transcription factor enrichment analyses, as well as disease-
related text mining for human liver enrichment genes. Liver
enrichment genes were primarily found in two groups of GO models:
immunity-related function models and metabolic processes involving
important biological components. As an important organ for remov-
ing pathogens and antigens from the blood, protein synthesis, and
metabolism, the liver requires a locally regulated immune response
[12]. The relationships between clinical consequences and liver
function have been widely studied. About 60% of all acute liver failure
(ALF) patients fulﬁll the criteria for systemic inﬂammatory response
syndrome (SIRS) [13,14]. Furthermore, ALF patients are likely to
display adrenal insufﬁciency, which might contribute to hemody-
namic compromise [15]. An active carboxylic acid metabolism
pathway would strongly stimulate liver glycogen synthetase, the
activation of which might coordinate hepatic glycogen deposition via
the functional tricarboxylic acid (TCA) cycle [16]. Functional disorders
in carboxylic acid metabolic processes could result in glycogen-
storage disease type 0 (GSD-0) or hepatic glycogen synthetase
deﬁciency [17].
To understand the mechanisms of transcriptional regulatory of
liver enrichment genes, we analyzed the bias of transcription factor
out of these liver enrichment genes using TRANSFAC database. WeDescription
%
7.0% Present in human (mouse) and absent in mouse (rat)
7.2% Expression level in human (mouse) is higher than that in mouse (rat)
56.3% Expression level in human (mouse) is similar to that in mouse (rat)
18.1% Expression level in human (mouse) is lower than that in mouse (rat)
4.4% Absent in human (mouse) and present in mouse (rat)
7.0% Absent in both species
Table 3
Pathway enrichment for homology pairs in human and mouse.
Type Pathway p-Value
I Cytokine-cytokine receptor interaction 3.19E-07
ECM-receptor interaction 7.12E-05
II Oxidative phosphorylation 2.27E-12
Carbon ﬁxation 4.66E-05
Proteasome 8.84E-05
Citrate cycle (TCA cycle) 1.22E-04
Ubiquinone biosynthesis 4.03E-04
III DNA polymerase 8.11E-05
Cell cycle 3.10E-04
IV Complement and coagulation cascades 7.04E-04
V Neuroactive ligand–receptor interaction 8.25E-09
Regulation of autophagy 2.05E-06
Cytokine-cytokine receptor interaction 3.42E-05
Calcium signaling pathway 2.16E-04
VI Neuroactive ligand–receptor interaction 9.85E-20
Cell Communication 2.28E-08
Regulation of autophagy 1.16E-04
Calcium signaling pathway 2.96E-04
Cytokine-cytokine receptor interaction 3.95E-04
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enriched for liver enrichment genes and for cell cycle-related genes.
It was reported that CEBPA is correlated with altered expression of
cell cycle-associated proteins, especially during liver regeneration
[18]. Hepatocyte nuclear factor-1alpha (HNF1A) is expressed
predominantly in the liver, and a number of genes contain multiple
promoter and enhancer regions regulated by different HNFs. HNFs
regulate the expression of a wide variety of target genes, including
the insulin gene as well as genes involved in glucose transport and
metabolism.
Reference text mining was conducted to discover potential
relationships between the identiﬁed liver enrichment genes and
various cancers, using an automated search strategy. Some liver
enrichment genes have been shown by genotypic and phenotypic
characterization to be putative tumor susceptibility genes in liver
cancer. For example, a study suggested that GNMT alteration may be
an early event in hepatocellular carcinoma (HCC) development and
that GNMT may be a new tumor susceptibility gene for HCC [19]. In
addition, the abnormal expression of liver enrichment genes in tissues
other than livermay be an important disease phenotype signature. For
instance, apoA-II has been shown to be over-expressed in the serum
of individuals with prostate cancer [20]. Under normal conditions the
expression of this gene is low in all tissues except liver and spleen.
These results suggest that the strategy employed for liver enrichment
gene identiﬁcation in our study could identify potential relationships
between genes and diseases.Table 4
Transcription factor usage bias for homology pairs in human and mouse.
Transcription factor TRANSFAC ID Pathway enrichment for homo
I II
JUN T00133 2.54E-06
AP-1 T00029 1.12E-03
POU1F1 T00691 3.99E-03
NFKB1 T00593 5.40E-03
NFKB1 T00590 2.94E-02
RELA T00594 3.64E-02
CEBPB T00581 4.46E-02
ESR1 T00261 1.08E-02
CEBPA T00108
Sp1 T00759
TFAP2A T00035
Gﬁ1 T01921
TP53 T00671
Sp3 T02338
USF1 T00874The physiological function of liver in human, mouse and rat is
similar, which is also represented by the similar expression pattern in
liver (Types II, III, IV and VI). Especially in mouse and rat liver, over
88% gene show shared expression levels at a broad level of “expressed
in both” and “absent in both.” Species speciﬁc function of liver is
reﬂected by the statistically signiﬁcantly differentially expressed
homologous genes (Types II and IV). Our results on species-speciﬁc
expression pattern of liver genes suggests that gene-targeted and
transgenic mouse models for the liver system might not accurately
reﬂect human corresponding physiology [21,22].
Liver enrichment genes function largely in metabolism and less in
neuron- and signaling-related pathways. Cross-species housekeeping
pathways such as cell cycle and DNA replication contain stably
expressed genes that are seen across different species. More strongly
expressed genes are largely concentrated in the pathways of oxidative
phosphorylation, carbon metabolism, the TCA cycle, ubiquinone
biosynthesis, and others. Oxidative phosphorylation (OXPHOS)
enzymes play key roles in liver regeneration and human hepatocellular
carcinoma [23]. According to Magnusson, the rate of Krebs cycle ﬂux is
inﬂuenced signiﬁcantly in the fasted state [24]. Our results suggest a
more active mechanism of substance and energy metabolism in this
context, as well as an altered response to environmental disturbances.
Transcription factor analysis revealed that the target genes of the
transcription factor CEBPA mainly contain genes from the Type III
group, an enriched class of cell cycle-related genes. NFKB1 is known to
be a key regulator of genes involved in responses to infection,
inﬂammation, and stress [25]. Most of the target gene of NF-kappaB
were expressed in all of human, mouse and rat liver. In our results, a
few targets of this transcription factor showed an association with
Type I genes, suggesting that a part of target genes of this protein are
expressed in human liver, however be not expressed in mouse liver or
have weak expression signal in mouse liver. The GO enrichment
results showed that defense/immunity protein activity (GO:
0006952) was also related to this group. Other transcription factors
also regulate liver enrichment functions. The transcription factor Sp1
is of the utmost importance for efﬁcient activation of promoters by
liver-enriched trans-activators [26], the targets of which are mainly
cross-species housekeeping genes. The mutant form of c-jun in fetal
livers might lead to extensive apoptosis of both hematopoietic cells
and hepatoblasts [27].
Though our study incorporated heterogeneous gene expression
proﬁling data to construct a liver transcriptome atlas, therewere several
potential limitations.We noticed that a great number of liver-expressed
UniGene clusters were detected in EST data only, with limited
annotation information. The quality of these genes might be relatively
restricted. Another restriction onourobservations is theaforementioned
limitation regarding the number of validated transcription regulationlogy pairs in human and mouse
III IV V VI
1.37E-02
6.47E-05
1.14E-02
9.16E-04
3.45E-02
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287Y. Yu et al. / Genomics 96 (2010) 281–289interactions. Thus, only key components (or well-studied parts) of the
transcription regulation network were considered in our analysis. For
the species-speciﬁc gene study, the notion that the inter-species
differences in liver gene expression are more signiﬁcant than the
intra-species differences (such as between different strains of mice)
seems to be accurate. In addition, only homologous gene pairs were
considered in our cross-species comparison. We concluded that a few
unique genes in these species might slightly inﬂuence certain enrich-
ment results. RNA-Seq is a recently developed approach to transcrip-
tome proﬁling using high-throughput sequencing technology [28,29].
Compared with liver RNA-Seq data [28], over 90% of liver expressed
genes (15882 out of 17396) detected in our work have been proved by
deep sequencing of liver transcriptome (Fig. S4). More RNA-seq data for
tissue (including liver) transcriptomes will be soon available, to provide
another precise measurement of levels of gene transcripts [30].
4. Materials and methods
4.1. Adult human livers and RNA extraction
Adult human liver tissues from 10 adult human were surgically
resected due to hemangioma in the liver. The samples were obtained
from the portion unaffected by the hemangioma and were immedi-
ately frozen in liquid nitrogen. All procedures and risks were
explained verbally, and patients provided written consent. The
samples were sectioned and conﬁrmed to be histologically normal.
All laboratory data assessing hepatic function were within normal
ranges, including serum alanine aminotransferase, aspartate amino-
transferase, gamma-glutamyl transpeptidase, alkaline phosphatase,
total bilirubin, albumin, prothrombin activity, glucose, cholesterol,
and triglycerides (data not shown). Serological tests for hepatitis B
surface antigen, hepatitis C virus antibodies, and human immunode-
ﬁciency virus antibodies also proved negative. Neither heavy alcohol
consumption nor the intake of prescription or other drugs was
observed before surgical resection.
In addition, mouse and rat adult liver tissues were obtained from
SIPPR-BK Experimental Animal Co. (Shanghai, China). Total RNA was
extracted according to the manufacturer's instructions, and RNase-
free DNase I was used to remove DNA contamination. Nucleic acid
concentration and purity were assessed at 260 nm using a spectro-
photometer (DU 530, Beckman-Coulter Inc., Fullerton, CA), and the
quality was assessed using an Agilent 2100 Bioanalyzer. In order to
address gene expression polymorphism, the total RNA from 10 livers
was pooled. This project and protocols for the investigation involving
human and animal tissues were approved by the ethics committee of
the Chinese National Human Genome Center (Shanghai, China).
4.2. Microarray hybridization and data analysis
The pooled RNA sample from ten human-liver RNAs in sameamount
were labeled and hybridized to HG-U133plus 2.0 high-density
oligonucleotide arrays (Affymetrix), which contains 54,675 probe sets
representing 19164 human genes and 15136 ESTs on a single array. One
μg of poly(A)+RNA was annealed to oligo(dT) and transcribed using
SurperScript II reverse transcriptase (Invitrogen, Carlsbad, CA), Labeling,
hybridization, washing and signal scan on the microarrays were
performed according to the manufacturer's instructions. Primary
image analysis of the arrays was performed by using GENECHIP 3.2
(Affymetrix, Santa Clara, CA), and normalization was performed using
Mas 5.0 software (Affymetrix). Only those transcripts that were
declared “present” and more than 50 intensity of ﬂuorescence were
taken into account. To assign a signal for a gene in human liver, we
selected the maximum normalized expression signal of all probe sets
matched to the gene if there are multiple probe sets for a gene. The
datasets have been submitted to GEO (GSM561873 and GSM561882).4.3. MPSS assay
MPSS was performed using RNA from the pooled livers and
evaluated for the presence of LZP markers and absence of AFP
markers. The mRNA was converted to cDNA and digested with DpnII.
The last DpnII site and the downstream 14 bases were cloned into
Megaclone vectors and their sequences were determined according to
the MPSS protocol. All data are available for download from our
website (http://202.127.18.238/hepatocytes/). This experiment was
performed by TaKaRa Co., Japan.
4.4. Semi-quantitative RT-PCR
Reverse transcription was performed in a 20-μl reaction system
that initially contained 2 μg of total RNA, 20 pmol of oligo-dT, and
DEPC-H2O to a total volume of 11 μl. The reaction was incubated at
70 °C for 5 min. After 5 min at 0 °C, 4 μl 5× buffer, 2 μl 0.1 M DTT, 2 μl
dNTP (10 mM), and 1 μl (200 U) SurperScript II reverse transcriptase
(Life Technologies) were added and the reaction was incubated at
42 °C for 2 h. For the PCR, beta-actin was used as a control to estimate
the quality of the cDNA (forward primer: 5'-TCACCCACACTGTGCC-
CATCTACGA-3' and reverse primer: 5'-CAGCGGAACCGCTCATTGCC
AATGG-3'). Each PCR was performed as follows: pre-denature at
94 °C, 5 min; denature at 94 °C, annealing at 55 °C, extend at 72 °C, 40
seconds; ﬁnally, the reaction was incubated at 72 °C for 7 min. The
PCR products were examined by electrophoresis in a 2% agarose gel.
4.5. Quantitative real-time RT-PCR
To further validate expression of genes of Type I-IV in human,
mouse and rat liver specimens, the relative mRNA level of candidate
gene was measured by a quantitative real-time RT-PCR using on the
TaKaRa PCR Thermal Cycler Dice Detection System and SYBR green
dye (TaKaRa, Japan) in the specimens of human liver, mouse liver and
rat liver according to the manufacturer's recommendation. A
housekeeping gene, β-actin was used as an internal control.
Measurements were repeated twice to ensure the reproducibility of
results. The mRNA level of each gene in all the samples was
normalized by comparing with the level in human liver. The average
Ct value of the β-actin gene was subtracted from the average Ct value
of each gene for each sample: gene ΔCt=(Avg. gene Ct−Avg. β-actin
Ct), gene ΔΔCt=(geneΔCt_HCC-geneΔCt_human liver). The fold
change (2-geneΔΔCt) of gene expression relative to β-actin of each
sample examined was calculated [31,32].
4.6. Data source
Additional expression data were obtained from the referenced
studies. Gene expression datasets were downloaded from theNCBI GEO
database. Three series of human liver-related geneexpression datawere
considered in this work, including eight replicates (all from GPL570:
GSE11045,GSE7117, GSE7741; list in Table S9). HumanSAGEGenie data
were obtained from the CGAP website (http://cgap.nci.nih.gov/) [33].
The microarray datasets of normal liver in mouse (GPL1261: GSE6210,
GSE10895) and rat (GPL1355: GSE5509, GSE9121) were also collected
from GEO (7 and 8 replicates from different experiments in mouse and
rat, respectively; Table S9). The expression data of proteins in normal
human tissues were acquired from the Human Protein Atlas (http://
www.proteinatlas.org/). The MPSS data of mouse normal tissues were
obtained from GEO (GSE1581).
4.7. Expression data pro-processing
Brieﬂy, normalization was performed on the microarray datasets,
using MAS 5.0 for background correction. We used MAS 5.0 absolute
detection to investigate the expression state of each probe [34]. The data
288 Y. Yu et al. / Genomics 96 (2010) 281–289were further ﬁltered based on the Present (P) versus Absent (A) call
percentage. Those genes mapped with at least one statistically proven
present probe set in any GSE were classiﬁed as expressed (liver-
expressed genes). We rank transformed the expression values of the
expressedgenes for each chip. Thep-rankvalueswere calculatedas rank
value divided by the total number of genes on the chip [35].
4.8. Human liver enrichment gene detection
Human liver enrichment genes were detected using MPSS data
from a large variety of normal human tissues (all 33 tissues, including
liver) and validated using published EST data from the NCBI. The
identiﬁcation of liver enrichment genes with MPSS and EST data was
conducted by utilizing a computational strategy of tissue-speciﬁc
gene identiﬁcation [36] as follows: MPSS and EST sequences are
mapped into genes. Let k be the number of sequences corresponding
to gene g in liver. The total number of sequences in genes in all tissues
is n. Given the total size of the libraries in liver (m) and in all tissues
(N), the probability of observing k or more sequences for gene g in
liver can be calculated by the formula:
PliverðgÞ = ∑
n
x N k
Pr K = xð Þ
Pr K = kð Þ = f k;N;m;nð Þ =
m
k
 
N−m
n−k
 
N
n
 
The Bonferroni correction [37] was used to adjust the p-values for
liver enrichment gene identiﬁcation based on the hypergeometric
distribution.
4.9. Detecting the expression level of homologous gene pairs
Homologous gene pairs between human andmouse (and between
human and rat) were derived from BioMart [38]. For each pair, one-
sided Wilcoxon tests [39] were performed on the p-rank values from
two comparison groups: human to mouse and human to rat. The
signiﬁcance threshold for accepting an alternative hypothesis was set
to 0.05. Considering the expression states of these genes, we divided
the homologous pairs into six groups: Type I (PA)—the gene is
expressed in human although its homolog in mouse (or rat) is not
expressed; Type II—while both genes are expressed, the expression
level of the human homolog is higher than that of the mouse (or rat);
Type III—the expression level is similar in human and mouse (or in
human and rat); Type IV—the expression level in human is lower than
that in mouse (or in rat); Type V (AP)—the gene is not expressed in
human, while its homolog in mouse (or rat) is expressed in the liver;
Type VI (AA)—both genes in the pair are not expressed in the liver.
4.10. Feature and function enrichment analysis
Weused a dataset enrichment strategy to reﬂect thedegree towhich
a certain group is overrepresented compared to the entire dataset. A
group of gene featureswere selected for this analysis. Gene information,
including identiﬁcations, sequences, GC-content information, and
chromosome location, were obtained using the NCBI and BioMart
databases. CpG islands were predicted on the promoters of each gene,
which were deﬁned as 5000 bp upstream of the transcription start site
(TSS) of each transcript [40]. The transcription regulation information
with experimental evidence was gathered from TRANSFAC [41]. The
hypergeometric distributionwasused in the enrichment analysis for GO
models, KEGG pathways, and transcription factors. A multiple test
correction (Bonferroni correction) [37] was employed to adjust the p-
values. All calculations were performed in the R platform. Text miningfor the relationship between genes and diseases was conducted using
the bioinformatics tools from theOmicsExplorerwebsite (http://omics.
biosino.org:14000/kweb/).
The data resource and analysis results are available in online at
doi:10.1016/j.ygeno.2010.08.003.
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